Lemuteporfin

Drug Profile

Lemuteporfin

Alternative Names: DRM-05; Lemuteporfin topical solution; Lemuteporphin; LTS; QLT-0074

Latest Information Update: 30 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Developer Dermira; QLT
  • Class Antineoplastics; Ethylene glycols; Porphyrins; Small molecules
  • Mechanism of Action Apoprotein stimulants; Immunosuppressants; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acne
  • Discontinued Autoimmune disorders; Benign prostatic hyperplasia; Male pattern baldness

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
  • 30 Jun 2015 Lemuteporfin is still in preclinical trials for Acne in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top